Safety of Everolimus and Pemetrexed in Lung Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Everolimus

"RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed."

DRUG

Pemetrexed

Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline

Trial Locations (5)

2050

Novartis Investigative Site, Camperdown

3000

Novartis Investigative Site, Leuven

3002

Novartis Investigative Site, Melbourne

20246

Novartis Investigative Site, Hamburg

50924

Novartis Investigative Site, Cologne

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY